Peringatan Keamanan

Oral LD50, intravenous LD50, and intramuscular LD50 in rat is 4000 mg/kg, 750 mg/kg, and 1500 mg/kg, respectively MSDS. Oral LD50, subcutaneous LD50, and intravenous LD50 in mouse is 3100 mg/kg, 1620 mg/kg, and 1492 mg/kg, respectively MSDS. There have been no reports of overdose with dehydrocholic acid.

Dehydrocholic acid

DB11622

small molecule approved investigational

Deskripsi

Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid A33022. It has been used for stimulation of biliary lipid secretion. The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

Struktur Molekul 2D

Berat 402.531
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) No pharmacokinetic data available.
Volume Distribusi No pharmacokinetic data available.
Klirens (Clearance) No pharmacokinetic data available.

Absorpsi

The duodenal experiment indicates that dehydrocholic acid is absorbed from the proximal small intestine A33022.

Metabolisme

The major site of metabolism is proposed to be the liver. The major metabolite accounting for 70% of total detectable metabolites is dihydroxymonoketo bile acid (3?,7?-dihydroxy-12-keto-5?-cholanoic acid). About 20% of metabolites is monohydroxydiketoacid (3?-hydroxy-7,12-keto-5?-cholanoic acid) and about 10% is cholic acid A33022.

Rute Eliminasi

Administered dehydrocholic acid is excreted rapidly in bile as glycine- and taurine-conjugated bile acids A33022.

Interaksi Obat

570 Data
Lepirudin The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid.
Bivalirudin The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Dehydrocholic acid.
Alteplase The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Dehydrocholic acid.
Urokinase The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Dehydrocholic acid.
Reteplase The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Dehydrocholic acid.
Anistreplase The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Dehydrocholic acid.
Tenecteplase The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Dehydrocholic acid.
Drotrecogin alfa The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Dehydrocholic acid.
Streptokinase The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Dehydrocholic acid.
Dicoumarol The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Dehydrocholic acid.
Argatroban The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Dehydrocholic acid.
Ardeparin The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Dehydrocholic acid.
Phenindione The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Dehydrocholic acid.
Fondaparinux The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Dehydrocholic acid.
Warfarin The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Dehydrocholic acid.
Pentosan polysulfate The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Dehydrocholic acid.
Phenprocoumon The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Dehydrocholic acid.
Heparin The risk or severity of bleeding and bruising can be increased when Heparin is combined with Dehydrocholic acid.
Enoxaparin The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Dehydrocholic acid.
Acenocoumarol The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Dehydrocholic acid.
4-hydroxycoumarin The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Dehydrocholic acid.
Coumarin The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Dehydrocholic acid.
Ximelagatran The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Dehydrocholic acid.
Desmoteplase The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Dehydrocholic acid.
Ancrod The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Dehydrocholic acid.
Rivaroxaban The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Dehydrocholic acid.
Sulodexide The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Dehydrocholic acid.
Semuloparin The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Dehydrocholic acid.
Idraparinux The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Dehydrocholic acid.
Astaxanthin The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Dehydrocholic acid.
Apixaban The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Dehydrocholic acid.
Otamixaban The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Dehydrocholic acid.
Amediplase The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Dehydrocholic acid.
Dabigatran etexilate The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Dehydrocholic acid.
Danaparoid The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Dehydrocholic acid.
Dalteparin The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Dehydrocholic acid.
Tinzaparin The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Dehydrocholic acid.
(R)-warfarin The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Dehydrocholic acid.
Ethyl biscoumacetate The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Dehydrocholic acid.
Nadroparin The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Dehydrocholic acid.
Ditazole The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Dehydrocholic acid.
Edoxaban The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Dehydrocholic acid.
Potassium citrate The risk or severity of dehydration can be increased when Potassium citrate is combined with Dehydrocholic acid.
Sodium citrate The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Dehydrocholic acid.
Dextran The risk or severity of bleeding and bruising can be increased when Dextran is combined with Dehydrocholic acid.
Bemiparin The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Dehydrocholic acid.
Parnaparin The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Dehydrocholic acid.
Desirudin The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Dehydrocholic acid.
Antithrombin Alfa The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Dehydrocholic acid.
Protein C The risk or severity of bleeding and bruising can be increased when Protein C is combined with Dehydrocholic acid.
Antithrombin III human The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Dehydrocholic acid.
Letaxaban The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Dehydrocholic acid.
Darexaban The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Dehydrocholic acid.
Betrixaban The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Dehydrocholic acid.
Nafamostat The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Dehydrocholic acid.
Monteplase The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Dehydrocholic acid.
Gabexate The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Dehydrocholic acid.
Fluindione The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Dehydrocholic acid.
Protein S human The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Dehydrocholic acid.
Brinase The risk or severity of bleeding and bruising can be increased when Brinase is combined with Dehydrocholic acid.
Clorindione The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Dehydrocholic acid.
Diphenadione The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Dehydrocholic acid.
Tioclomarol The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Dehydrocholic acid.
Melagatran The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Dehydrocholic acid.
Saruplase The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Dehydrocholic acid.
(S)-Warfarin The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Dehydrocholic acid.
Tocopherylquinone The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Dehydrocholic acid.
Dabigatran The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Dehydrocholic acid.
Troxerutin The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Dehydrocholic acid.
Edetic acid The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Dehydrocholic acid.
Reviparin The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Dehydrocholic acid.
Dermatan sulfate The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Dehydrocholic acid.
SR-123781A The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Dehydrocholic acid.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Dehydrocholic acid.
Eptifibatide The risk or severity of adverse effects can be increased when Eptifibatide is combined with Dehydrocholic acid.
Ticlopidine The risk or severity of adverse effects can be increased when Ticlopidine is combined with Dehydrocholic acid.
Anagrelide The risk or severity of adverse effects can be increased when Anagrelide is combined with Dehydrocholic acid.
Clopidogrel The risk or severity of adverse effects can be increased when Clopidogrel is combined with Dehydrocholic acid.
Tirofiban The risk or severity of adverse effects can be increased when Tirofiban is combined with Dehydrocholic acid.
Pentoxifylline The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Dehydrocholic acid.
Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dehydrocholic acid.
Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dehydrocholic acid.
Sulfinpyrazone The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Dehydrocholic acid.
Cilostazol The risk or severity of adverse effects can be increased when Cilostazol is combined with Dehydrocholic acid.
Ridogrel The risk or severity of adverse effects can be increased when Ridogrel is combined with Dehydrocholic acid.
Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dehydrocholic acid.
Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Dehydrocholic acid.
Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Dehydrocholic acid.
Tesmilifene The risk or severity of adverse effects can be increased when Tesmilifene is combined with Dehydrocholic acid.
Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Dehydrocholic acid.
Beraprost The risk or severity of adverse effects can be increased when Beraprost is combined with Dehydrocholic acid.
Ibudilast The risk or severity of adverse effects can be increased when Ibudilast is combined with Dehydrocholic acid.
Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Dehydrocholic acid.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dehydrocholic acid.
Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Dehydrocholic acid.
Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Dehydrocholic acid.
Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Dehydrocholic acid.
Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Dehydrocholic acid.
Ticagrelor The risk or severity of adverse effects can be increased when Ticagrelor is combined with Dehydrocholic acid.
Icosapent ethyl The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Dehydrocholic acid.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 4685091
    Soloway RD, Hofmann AF, Thomas PJ, Schoenfield LJ, Klein PD: Triketocholanoic (dehydrocholic) acid. Hepatic metabolism and effect on bile flow and biliary lipid secretion in man. J Clin Invest. 1973 Mar;52(3):715-24. doi: 10.1172/JCI107233.
  • PMID: 2340963
    Yousef IM, Mignault D, Weber AM, Tuchweber B: Influence of dehydrocholic acid on the secretion of bile acids and biliary lipids in rats. Digestion. 1990;45(1):40-51. doi: 10.1159/000200223.
  • PMID: 1502488
    Chanussot F, Domingo N, Tuchweber B, Lafont H, Yousef I: Influence of dehydrocholic and cholic acids on the biliary secretion of anionic polypeptide fraction, the major apoprotein of the biliary lipoprotein complex. Scand J Gastroenterol. 1992;27(3):238-42.
  • PMID: 2241901
    Chanussot F, Lafont H, Hauton J, Tuchweber B, Yousef I: Studies on the origin of biliary phospholipid. Effect of dehydrocholic acid and cholic acid infusions on hepatic and biliary phospholipids. Biochem J. 1990 Sep 15;270(3):691-5.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Acidobyl
    Tablet • - • Oral • Canada • OTC • Approved
  • Duchol Ect
    Tablet, delayed release • - • Oral • Canada • OTC • Approved
  • Dycholium Tablet 300mg
    Tablet • 300 mg • Oral • Canada • OTC • Approved
  • Dycholium Tablet 300mg
    Tablet • 300 mg • Oral • Canada • OTC • Approved
  • Medichol
    Tablet • - • Oral • Canada • Approved
  • Regubil
    Tablet • - • Oral • Canada • OTC • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul